NCT06437223View on ClinicalTrials.gov

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
Long COVID
Interventions
DRUG

Tonabersat

Tonabersat 40mg. Two tablets per day

DRUG

Placebo

Placebo 40mg, Two tablets per day

Trial Locations (1)

02451

RECRUITING

Massachusetts Eye Research and Surgery Institution (MERSI), Waltham

Sponsors
All Listed Sponsors
lead

Inflammx Therapeutics Inc

INDUSTRY